Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Gildeuretinol Data Will Be Presented During the 13th International FLORetina ICOOR Congress December 4–7 in Florence, Italy

Alkeus Pharmaceuticals announces gildeuretinol data will be presented during the 13th International FLORetina ICOOR Congress Dec. 4–7 in Florence, Italy
December 02, 2025 08:00 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Appoints Renowned Retina Specialist and Biotech Executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer

Alkeus Pharmaceuticals appoints renowned retina specialist and biotech executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer
October 09, 2025 10:35 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, October 18-21 in Orlando

CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...
August 07, 2025 10:15 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Presentation of Positive Interim TEASE-3 Study Data in Early-Stage Stargardt Disease Patients Treated with Oral Gildeuretinol

Alkeus Pharmaceuticals, Inc. today announced the presentation of an interim data update from its TEASE-3 study in early-stage Stargardt disease.
July 23, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2

Alkeus Pharmaceuticals announces gildeuretinol data presentations during the American Society of Retina Specialists (ASRS) 43rd Annual Meeting.
May 07, 2025 08:59 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Alkeus Pharmaceuticals presents gildeuretinol data during the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
April 24, 2025 10:59 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Presentations of Gildeuretinol Data During the Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Alkeus Pharmaceuticals announces presentations of gildeuretinol data in Stargardt and GA during ARVO May 4-8
February 25, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Establishment of Scientific Advisory Board

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...
February 11, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025

CAMBRIDGE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...
January 09, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients

Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A total of five patients have completed the 24-month...